Cosmos Health Q3 Revenue Rises 38% to $17.1 Million

Reuters11-17

<a href="https://laohu8.com/S/COSM">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million

Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584062154?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584062154","market":"nz","top_or_hot":-1,"title":"Cosmos Health Q3 Revenue Rises 38% to $17.1 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COSM\">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cosmos Health Q3 Revenue Rises 38% to $17.1 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCosmos Health Q3 Revenue Rises 38% to $17.1 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 22:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COSM\">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COSM","symbol_name":"COSMOS HEALTH INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL77V60m:1","article_id":"2584062154","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584062154","pubTimestamp":1763388988,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income  per share improved to $ from $ in Q3 2024, and adjusted EPS improved to $ from $. For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $ last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing fa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COSM":"COSMOS HEALTH INC","BK4175":"保健护理产品经销商"},"translate_title":"Cosmos Health第三季度收入增长38%至1710万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COSM":0.9},"content_text":"Cosmos Health Q3 Revenue Rises 38% to $17.1 Million\n    \n\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584062154","isCrawlerRequest":true}